APA (7th ed.) Citation

A, S., RF, B., HE, J., UH, M., A, W., P, G., . . . K, D. (2022). Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC cancer, 22(1), 147. https://doi.org/10.1186/s12885-022-09184-1

Chicago Style (17th ed.) Citation

A, Schmitz, et al. "Longitudinal Minimal Residual Disease Assessment in Multiple Myeloma Patients in Complete Remission - Results from the NMSG Flow-MRD Substudy Within the EMN02/HO95 MM Trial." BMC Cancer 22, no. 1 (2022): 147. https://doi.org/10.1186/s12885-022-09184-1.

MLA (9th ed.) Citation

A, Schmitz, et al. "Longitudinal Minimal Residual Disease Assessment in Multiple Myeloma Patients in Complete Remission - Results from the NMSG Flow-MRD Substudy Within the EMN02/HO95 MM Trial." BMC Cancer, vol. 22, no. 1, 2022, p. 147, https://doi.org/10.1186/s12885-022-09184-1.